{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:14:23Z","timestamp":1772558063488,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.vaccine.2016.01.037","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T01:43:36Z","timestamp":1454377416000},"page":"1247-1251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication"],"prefix":"10.1016","volume":"34","author":[{"given":"Rosanne W.","family":"Wieten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile F.F.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan K.J.","family":"Pieren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caspar J.","family":"Hodiamont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter P.A.M.","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.M.","family":"van Gorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00ebtte W.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.01.037_bib0160","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.037_bib0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine\u2014how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.037_bib0170","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"issue":"20","key":"10.1016\/j.vaccine.2016.01.037_bib0175","first-page":"210","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2013\u2014conclusions and recommendations","volume":"88","author":"World Health Organization","year":"2013","journal-title":"Weekly Epidem Rec"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.037_bib0180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.037_bib0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1590\/S0034-89102005000300012","article-title":"Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial","volume":"39","author":"Camacho","year":"2005","journal-title":"Rev Saude Publica"},{"issue":"25","key":"10.1016\/j.vaccine.2016.01.037_bib0190","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2016.01.037_bib0195","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"RR-7","key":"10.1016\/j.vaccine.2016.01.037_bib0200","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.037_bib0205","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2007.77.919","article-title":"Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters","volume":"77","author":"Mateo","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.037_bib0210","first-page":"131","article-title":"Fatal myelomeningoencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J Med Assoc Thai"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.037_bib0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination of 102 HIV infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.037_bib0220","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/QAI.0b013e318249de59","article-title":"Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV infected patients","volume":"59","author":"Pacanowski","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.037_bib0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2012.04.002","article-title":"Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali","volume":"106","author":"Sidibe","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.037_bib0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S0037-86822009000100006","article-title":"Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases","volume":"42","author":"Mota","year":"2009","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.037_bib0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-3062.2011.00686.x","article-title":"Yellow fever vaccination in organ transplanted patients: is it safe?. A multicentre study","volume":"14","author":"Azevedo","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.037_bib0240","series-title":"Module 8, Yellow Fever","article-title":"The immunological basis for immunization series","author":"World Health Organization","year":"1996"},{"key":"10.1016\/j.vaccine.2016.01.037_bib0245","series-title":"Meeting report, WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines","author":"World Health Organization","year":"2009"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.037_bib0250","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0035-9203(81)90335-7","article-title":"Indirect fluorescent antibody test for the diagnosis of yellow fever","volume":"75","author":"Monath","year":"1981","journal-title":"Trans R Soc Trop Med and Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.037_bib0255","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/oxfordjournals.aje.a121232","article-title":"Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans","volume":"93","author":"Monath","year":"1970","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.037_bib0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CVI.00078-07","article-title":"Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus","volume":"15","author":"Niedrig","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.01.037_bib0265","series-title":"Dutch national guidelines on travellers\u2019 medicine","author":"LCR","year":"2007"},{"issue":"10","key":"10.1016\/j.vaccine.2016.01.037_bib0270","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/340104","article-title":"Prevention of yellow fever in persons traveling to the tropics","volume":"34","author":"Monath","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.037_bib0275","first-page":"113","article-title":"A simple micro-culture method for the study of group B arbovirusses","volume":"40","author":"De Madrid","year":"1969","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2016.01.037_bib0280","first-page":"23","article-title":"Requirements for yellow fever vaccine","volume":"594","author":"World Health Organization","year":"1976","journal-title":"WHO Tech Rep Ser"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.037_bib0285","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","article-title":"Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay","volume":"131","author":"Cohen","year":"2006","journal-title":"J Virol Methods"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2016.01.037_bib0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0166-3542(96)89697-5","article-title":"Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections","volume":"30","author":"Neyts","year":"1996","journal-title":"Antiviral res"},{"key":"10.1016\/j.vaccine.2016.01.037_bib0295","unstructured":"Personal correspondence, Department of Toxicology, Leiden University Medical Center."},{"key":"10.1016\/j.vaccine.2016.01.037_bib0300","series-title":"Guide to vaccine contraindications and precautions","author":"Centers for Disease Control and prevention","year":"2008"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.037_bib0305","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases","volume":"42","author":"Grim","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.037_bib0310","doi-asserted-by":"crossref","first-page":"e36291","DOI":"10.1371\/journal.pone.0036291","article-title":"First international external quality assessment study on molecular and serological methods for yellow fever diagnosis","volume":"7","author":"Domingo","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T05:15:55Z","timestamp":1572326155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0264410X16000815"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}